Related Experiment Video
Updated: Jun 17, 2026
10:28
Probe-based Real-time PCR Approaches for Quantitative Measurement of microRNAs
Published on: April 14, 2015
Assessment of siRNA pharmacokinetics using ELISA-based quantification
Eun-Joong Kim1, Tae Gwan Park, Yu-Kyoung Oh
1National Research Laboratory for Transporters Targeted Drug Design, Seoul National University, 599 Gwanangno, Gwanak-gu, Seoul 151-742, South Korea.
Summary
A new ELISA assay accurately quantifies double-stranded small interfering RNAs (siRNAs) for pharmacokinetic studies. Methylated siRNAs show improved blood concentration and prolonged profiles, especially when complexed with liposomes.
Area of Science:
- Biotechnology
- Pharmacology
- Molecular Biology
Background:
- Small interfering RNAs (siRNAs) are crucial for gene silencing but require robust quantification methods for in vivo studies.
- Existing quantification methods for siRNAs, such as fluorometric analysis, lack the sensitivity and specificity needed for pharmacokinetic profiling.
- Chemical modifications, like methylation, can enhance siRNA stability and efficacy, necessitating assays that can differentiate modified from unmodified forms.
Purpose of the Study:
- To develop and validate a novel, highly sensitive enzyme-linked immunosorbent assay (ELISA) for quantifying double-stranded intact siRNAs.
- To compare the pharmacokinetic profiles of methylated versus unmethylated siRNAs administered intravenously.
- To evaluate the impact of cationic liposome complexation on the pharmacokinetics of methylated siRNAs.
Main Methods:
- Development of a dual-labeled (biotin and dinitrophenol) ELISA assay for double-stranded siRNA detection.
- Validation of the assay's linearity, sensitivity, precision (intra- and inter-assay CV), and specificity for double-stranded siRNAs.
- Application of the ELISA assay to quantify siRNA levels in cell cultures (A549, HeLa) and in vivo pharmacokinetic studies following intravenous administration.
Main Results:
- The developed ELISA assay demonstrated high sensitivity (5.4 fmol/ml) and linearity (10-100 fmol/ml), significantly outperforming fluorometric methods.
- The assay showed excellent specificity for double-stranded siRNAs, with minimal signal detected for single-stranded RNA.
- Methylated siRNAs were found at higher levels in cells and exhibited superior pharmacokinetic profiles (higher blood concentration, prolonged duration) compared to unmethylated siRNAs.
- Complexation with DOTAP-based liposomes further enhanced the pharmacokinetic profile of methylated siRNAs, reducing clearance rate by 2.2-fold.
Conclusions:
- The novel ELISA-based assay provides a sensitive, specific, and reliable method for quantifying double-stranded siRNAs in pharmacokinetic analyses.
- Methylation is a promising chemical modification for improving siRNA delivery and pharmacokinetic behavior.
- Cationic liposome complexation can significantly enhance the in vivo performance of methylated siRNAs, supporting their development as therapeutic agents.
